These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 30550622

  • 1. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.
    Pang Y, Holmes MV, Chen Z, Kartsonaki C.
    J Gastroenterol Hepatol; 2019 Feb; 34(2):330-345. PubMed ID: 30550622
    [Abstract] [Full Text] [Related]

  • 2. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
    Yu J, Ploner A, Kordes M, Löhr M, Nilsson M, de Maturana MEL, Estudillo L, Renz H, Carrato A, Molero X, Real FX, Malats N, Ye W.
    Int J Cancer; 2021 Apr 15; 148(8):2048-2058. PubMed ID: 33411965
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters.
    Urayama S.
    World J Gastroenterol; 2015 Feb 14; 21(6):1707-17. PubMed ID: 25684935
    [Abstract] [Full Text] [Related]

  • 5. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study.
    Ríos Peces S, Díaz Navarro C, Márquez López C, Caba O, Jiménez-Luna C, Melguizo C, Prados JC, Genilloud O, Vicente Pérez F, Pérez Del Palacio J.
    SLAS Discov; 2017 Apr 14; 22(4):348-359. PubMed ID: 27655283
    [Abstract] [Full Text] [Related]

  • 6. Development of a Fit-For-Purpose Multi-Marker Panel for Early Diagnosis of Pancreatic Ductal Adenocarcinoma.
    Kim H, Huh S, Park J, Han Y, Ahn KG, Noh Y, Lee SJ, Chu H, Kim SS, Jung HS, Yun WG, Cho YJ, Kwon W, Jang JY, Kang UB.
    Mol Cell Proteomics; 2024 Sep 14; 23(9):100824. PubMed ID: 39097268
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
    Debernardi S, O'Brien H, Algahmdi AS, Malats N, Stewart GD, Plješa-Ercegovac M, Costello E, Greenhalf W, Saad A, Roberts R, Ney A, Pereira SP, Kocher HM, Duffy S, Blyuss O, Crnogorac-Jurcevic T.
    PLoS Med; 2020 Dec 14; 17(12):e1003489. PubMed ID: 33301466
    [Abstract] [Full Text] [Related]

  • 9. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project.
    Bardol T, Dujon AM, Taly V, Dunyach-Remy C, Lavigne JP, Costa-Silva B, Kurma K, Eslami-S Z, Cayrefourcq L, Canivet C, Muscari F, Bournet B, Alix-Panabières C.
    BMC Cancer; 2024 Jun 10; 24(1):709. PubMed ID: 38853244
    [Abstract] [Full Text] [Related]

  • 10. Advances in pancreatic cancer research: moving towards early detection.
    He XY, Yuan YZ.
    World J Gastroenterol; 2014 Aug 28; 20(32):11241-8. PubMed ID: 25170208
    [Abstract] [Full Text] [Related]

  • 11. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer.
    Byeon S, McKay MJ, Molloy MP, Gill AJ, Samra JS, Mittal A, Sahni S.
    Int J Cancer; 2024 Jul 15; 155(2):365-371. PubMed ID: 38519999
    [Abstract] [Full Text] [Related]

  • 12. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
    Hanna-Sawires RG, Schiphuis JH, Wuhrer M, Vasen HFA, van Leerdam ME, Bonsing BA, Mesker WE, van der Burgt YEM, Tollenaar RAEM.
    Int J Mol Sci; 2021 Mar 06; 22(5):. PubMed ID: 33800786
    [Abstract] [Full Text] [Related]

  • 13. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.
    Kandimalla R, Shimura T, Mallik S, Sonohara F, Tsai S, Evans DB, Kim SC, Baba H, Kodera Y, Von Hoff D, Chen X, Goel A.
    Ann Surg; 2022 Jan 01; 275(1):e229-e237. PubMed ID: 32398486
    [Abstract] [Full Text] [Related]

  • 14. A Predictive Noninvasive Single-Nucleotide Variation-Based Biomarker Signature for Resectable Pancreatic Cancer: Protocol for a Prospective Validation Study.
    Seeger N, Gutknecht S, Zschokke I, Fleischmann I, Roth N, Metzger J, Weber M, Breitenstein S, Grochola LF.
    JMIR Res Protoc; 2024 May 13; 13():e54042. PubMed ID: 38635586
    [Abstract] [Full Text] [Related]

  • 15. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
    Balasenthil S, Huang Y, Liu S, Marsh T, Chen J, Stass SA, KuKuruga D, Brand R, Chen N, Frazier ML, Jack Lee J, Srivastava S, Sen S, McNeill Killary A.
    J Natl Cancer Inst; 2017 Aug 01; 109(8):. PubMed ID: 28376184
    [Abstract] [Full Text] [Related]

  • 16. Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma.
    Li Q, Wang H, Zogopoulos G, Shao Q, Dong K, Lv F, Nwilati K, Gui XY, Cuggia A, Liu JL, Gao ZH.
    Oncotarget; 2016 Nov 22; 7(47):77838-77853. PubMed ID: 27788482
    [Abstract] [Full Text] [Related]

  • 17. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J, Kalthoff H, Reszka R, Kamlage B, Peter E, Schniewind B, González Maldonado S, Pilarsky C, Heidecke CD, Schatz P, Distler M, Scheiber JA, Mahajan UM, Weiss FU, Grützmann R, Lerch MM.
    Gut; 2018 Jan 22; 67(1):128-137. PubMed ID: 28108468
    [Abstract] [Full Text] [Related]

  • 18. Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.
    Yako YY, Kruger D, Smith M, Brand M.
    PLoS One; 2016 Jan 22; 11(5):e0154016. PubMed ID: 27170998
    [Abstract] [Full Text] [Related]

  • 19. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR, Postier RG, Li M, Lerner MR, Lightfoot SA, Peyton MD, Deb SJ, Baker CM, Williams TL, Hanas RJ, Stowell DE, Lander TJ, Brackett DJ, Hanas JS.
    Cancer Lett; 2015 Apr 10; 359(2):314-24. PubMed ID: 25637792
    [Abstract] [Full Text] [Related]

  • 20. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
    Dimitrakopoulos C, Vrugt B, Flury R, Schraml P, Knippschild U, Wild P, Hoerstrup S, Henne-Bruns D, Wuerl P, Graf R, Breitenstein S, Bond G, Beerenwinkel N, Grochola LF.
    JAMA Surg; 2019 Jun 01; 154(6):e190484. PubMed ID: 30942874
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.